Treatment of antineutrophil cytoplasmic antibodyassociated vasculitis with rituximab

Rodrigo Cartin-Cebaa, Fernando C. Fervenzab, Ulrich Specks

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

RTX is the first proven alternative to CYC for remission induction in severe GPA and MPA. RTX is the preferred agent for patients presenting with severe disease flares, and its use had become the de facto standard of care for patients with chronically relapsing refractory GPA. Its use in EGPA requires further investigation.

Original languageEnglish (US)
Pages (from-to)15-23
Number of pages9
JournalCurrent Opinion in Rheumatology
Volume24
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Remission Induction
Proxy
Standard of Care
Vasculitis
Therapeutics
Rituximab

Keywords

  • Antineutrophil cytoplasmic antibody
  • Antineutrophil cytoplasmic antibody associated vasculitis
  • Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
  • Granulomatosis with polyangiitis (Wegener's granulomatosis)
  • Microscopic polyangiitis
  • Rituximab
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Treatment of antineutrophil cytoplasmic antibodyassociated vasculitis with rituximab. / Cartin-Cebaa, Rodrigo; Fervenzab, Fernando C.; Specks, Ulrich.

In: Current Opinion in Rheumatology, Vol. 24, No. 1, 01.2012, p. 15-23.

Research output: Contribution to journalArticle

Cartin-Cebaa, Rodrigo ; Fervenzab, Fernando C. ; Specks, Ulrich. / Treatment of antineutrophil cytoplasmic antibodyassociated vasculitis with rituximab. In: Current Opinion in Rheumatology. 2012 ; Vol. 24, No. 1. pp. 15-23.
@article{3c2bed8626d44e1fa324a92d43b6f139,
title = "Treatment of antineutrophil cytoplasmic antibodyassociated vasculitis with rituximab",
abstract = "RTX is the first proven alternative to CYC for remission induction in severe GPA and MPA. RTX is the preferred agent for patients presenting with severe disease flares, and its use had become the de facto standard of care for patients with chronically relapsing refractory GPA. Its use in EGPA requires further investigation.",
keywords = "Antineutrophil cytoplasmic antibody, Antineutrophil cytoplasmic antibody associated vasculitis, Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), Granulomatosis with polyangiitis (Wegener's granulomatosis), Microscopic polyangiitis, Rituximab, Vasculitis",
author = "Rodrigo Cartin-Cebaa and Fervenzab, {Fernando C.} and Ulrich Specks",
year = "2012",
month = "1",
doi = "10.1097/BOR.0b013e32834d5730",
language = "English (US)",
volume = "24",
pages = "15--23",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Treatment of antineutrophil cytoplasmic antibodyassociated vasculitis with rituximab

AU - Cartin-Cebaa, Rodrigo

AU - Fervenzab, Fernando C.

AU - Specks, Ulrich

PY - 2012/1

Y1 - 2012/1

N2 - RTX is the first proven alternative to CYC for remission induction in severe GPA and MPA. RTX is the preferred agent for patients presenting with severe disease flares, and its use had become the de facto standard of care for patients with chronically relapsing refractory GPA. Its use in EGPA requires further investigation.

AB - RTX is the first proven alternative to CYC for remission induction in severe GPA and MPA. RTX is the preferred agent for patients presenting with severe disease flares, and its use had become the de facto standard of care for patients with chronically relapsing refractory GPA. Its use in EGPA requires further investigation.

KW - Antineutrophil cytoplasmic antibody

KW - Antineutrophil cytoplasmic antibody associated vasculitis

KW - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

KW - Granulomatosis with polyangiitis (Wegener's granulomatosis)

KW - Microscopic polyangiitis

KW - Rituximab

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=82955227492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955227492&partnerID=8YFLogxK

U2 - 10.1097/BOR.0b013e32834d5730

DO - 10.1097/BOR.0b013e32834d5730

M3 - Article

C2 - 22089095

AN - SCOPUS:82955227492

VL - 24

SP - 15

EP - 23

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 1

ER -